Eliem Therapeutics (ELYM) Institutional Ownership $1.52 -0.07 (-4.40%) As of 02/14/2025 Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Eliem Therapeutics (NASDAQ:ELYM)CurrentInstitutional OwnershipPercentage69.76%Number ofInstitutional Buyers(last 12 months)24TotalInstitutional Inflows(last 12 months)$30.66MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$4.31M Get ELYM Insider Trade Alerts Want to know when executives and insiders are buying or selling Eliem Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ELYM Institutional Buying and Selling by Quarter Eliem Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails12/26/2024 JPMorgan Chase & Co.12,776$65K0.0%+311.6%0.043% 11/19/2024 Barclays PLC38,859$198K0.0%+1,428.1%0.131% 11/15/2024 Barclays PLC38,859$198K0.0%+1,428.1%0.131% 11/15/2024 Jane Street Group LLC10,907$56K0.0%N/A0.037% 11/15/2024 Sphera Funds Management LTD.181,970$926K0.1%-15.4%0.612% 11/15/2024 State Street Corp315,036$1.60M0.0%+433.9%1.059% 11/15/2024 Samsara BioCapital LLC2,609,114$13.28M2.6%-20.0%8.770% 11/15/2024 Point72 Asset Management L.P.590,946$3.01M0.0%N/A1.986% 11/15/2024 Parkman Healthcare Partners LLC278,775$1.42M0.2%N/A0.937% 11/15/2024 Ikarian Capital LLC175,100$891K0.1%+75.1%0.589% Get the Latest News and Ratings for ELYM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024 Janus Henderson Group PLC3,606,495$18.30M0.0%+10.8%12.122% 11/14/2024 Ally Bridge Group NY LLC1,229,292$6.26M3.3%+145.9%4.132% 11/14/2024 MetLife Investment Management LLC17,769$90K0.0%N/A0.060% 11/13/2024 Great Point Partners LLC248,168$1.26M0.4%N/A0.834% 11/13/2024 Advantage Alpha Capital Partners LP48,169$245K0.1%N/A0.162% 11/13/2024 The Manufacturers Life Insurance Company49,524$252K0.0%N/A0.166% 11/12/2024 Valence8 US LP12,045$61K0.0%N/A0.040% 11/12/2024 Charles Schwab Investment Management Inc.70,093$357K0.0%+309.2%0.236% 11/8/2024 Segall Bryant & Hamill LLC58,411$297K0.0%N/A0.196% 10/29/2024 Chicago Partners Investment Group LLC16,966$81K0.0%N/A0.057% 10/3/2024 SG Americas Securities LLC11,715$60K0.0%N/A0.039% 8/16/2024 Driehaus Capital Management LLC696,057$4.95M0.0%-14.2%2.340% 8/15/2024 Affinity Asset Advisors LLC1,670,661$11.88M1.4%N/A5.615% 8/14/2024 Ally Bridge Group NY LLC500,000$3.56M2.1%N/A1.681% 8/9/2024 Renaissance Technologies LLC37,000$263K0.0%+248.5%0.124% 8/9/2024 Dimensional Fund Advisors LP12,560$89K0.0%N/A0.042% 8/1/2024 Rhumbline Advisers8,233$59K0.0%N/A0.028% 7/26/2024 Bank of New York Mellon Corp18,845$134K0.0%N/A0.063% 4/23/2024 BML Capital Management LLC2,193,742$6.01M4.0%+0.6%7.914% 1/30/2024 BML Capital Management LLC2,180,000$5.89M4.4%+12.5%7.907% 1/26/2024 Cerity Partners LLC13,821$37K0.0%N/A0.050% 11/13/2023 Silverarc Capital Management LLC121,110$319K0.1%-75.5%0.447% 10/23/2023 BML Capital Management LLC1,938,263$5.10M4.7%+22.4%7.155% 8/15/2023 Silverarc Capital Management LLC494,089$1.38M0.4%+1.7%1.830% 8/14/2023 Driehaus Capital Management LLC810,593$2.27M0.0%+20.3%3.003% 7/24/2023 BML Capital Management LLC1,583,170$4.43M4.0%-4.5%5.866% 4/14/2023 BML Capital Management LLC1,658,170$4.81M4.2%-9.1%6.148% 2/14/2023 Driehaus Capital Management LLC551,942$2.03M0.0%+58.3%2.077% 2/13/2023 BML Capital Management LLC1,825,134$6.70M6.4%N/A6.869% 2/1/2023 Bank of Montreal Can25,244$93K0.0%N/A0.095% Collect $7k per month from Tesla’s SECRET dividend (Ad)There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?Click here to uncover Tesla's hidden income secret.11/8/2022 Atom Investors LP67,074$217K0.1%+154.9%0.252% 10/28/2022 Silverarc Capital Management LLC402,088$1.30M0.4%-43.6%1.513% 8/16/2022 Parkwood LLC67,202$67K0.2%+63.4%0.253% 7/25/2022 Silverarc Capital Management LLC713,009$2.15M0.7%+707.7%2.684% 5/12/2022 Monashee Investment Management LLC227,201$1.91M0.6%-24.3%0.855% 5/9/2022 Qube Research & Technologies Ltd15,874$133K0.0%N/A0.060% 2/19/2022 Woodline Partners LP373,368$3.91M0.1%-3.6%1.406% 2/15/2022 Samlyn Capital LLC1,703,546$17.82M0.2%+1.3%6.417% 2/11/2022 Parkwood LLC30,609$320K0.1%N/A0.115% 2/7/2022 Monashee Investment Management LLC300,000$3.14M0.8%-1.7%1.130% 2/2/2022 New York State Common Retirement Fund3,359$35K0.0%N/A0.013% 1/28/2022 Allspring Global Investments Holdings LLC2,880$30K0.0%N/A0.011% 12/29/2021 Hudson Bay Capital Management LP100,000$1.80M0.0%N/A0.377% 11/15/2021 Tudor Investment Corp Et Al287,294$5.17M0.0%N/A1.082% 11/15/2021 RA Capital Management L.P.13,150,849$236.45M3.3%N/A49.536% 11/15/2021 Caas Capital Management LP75,000$1.35M0.0%N/A0.283% 11/12/2021 Geode Capital Management LLC76,904$1.38M0.0%N/A0.290% 11/10/2021 Goldman Sachs Group Inc.165,952$2.98M0.0%N/A0.625% 11/9/2021BlackRock Inc.332,126$5.97M0.0%N/A1.251% 11/9/2021 Monashee Investment Management LLC305,233$5.49M1.0%N/A1.150% 11/4/2021 Deutsche Bank AG4,063$73K0.0%N/A0.015% (Data available from 1/1/2016 forward) ELYM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ELYM shares? During the previous two years, 29 institutional investors and hedge funds held shares of Eliem Therapeutics. The most heavily invested institutionals were Janus Henderson Group PLC ($18.30M), Samsara BioCapital LLC ($13.28M), Affinity Asset Advisors LLC ($11.88M), Ally Bridge Group NY LLC ($6.26M), BML Capital Management LLC ($6.01M), Driehaus Capital Management LLC ($4.95M), and Point72 Asset Management L.P. ($3.01M).Learn more on ELYM's institutional investors. What percentage of Eliem Therapeutics stock is owned by institutional investors? 69.76% of Eliem Therapeutics stock is owned by institutional investors. Learn more on ELYM's institutional investor holdings. Which institutional investors have been buying Eliem Therapeutics stock? Of the 27 institutional investors that purchased Eliem Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Affinity Asset Advisors LLC ($1.67M), Ally Bridge Group NY LLC ($1.23M), BML Capital Management LLC ($610.57K), Point72 Asset Management L.P. ($590.95K), Janus Henderson Group PLC ($352.51K), Parkman Healthcare Partners LLC ($278.78K), and State Street Corp ($256.03K). How much institutional buying is happening at Eliem Therapeutics? Institutional investors have bought a total of 5,897,710 shares in the last 24 months. This purchase volume represents approximately $32.69M in transactions. Which Eliem Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Eliem Therapeutics stock in the last 24 months: Samsara BioCapital LLC ($652.28K), Silverarc Capital Management LLC ($372.98K), BML Capital Management LLC ($241.96K), Driehaus Capital Management LLC ($115.62K), and Sphera Funds Management LTD. ($33.21K). How much institutional selling is happening at Eliem Therapeutics? Institutional investors have sold a total of 1,416,054 shares in the last 24 months. This volume of shares sold represents approximately $5.99M in transactions. Related Companies Lyell Immunopharma Major Shareholders TuHURA Biosciences Major Shareholders Zentalis Pharmaceuticals Major Shareholders CARGO Therapeutics Major Shareholders Vaxart Major Shareholders Acrivon Therapeutics Major Shareholders Cidara Therapeutics Major Shareholders Alector Major Shareholders Aclaris Therapeutics Major Shareholders Inhibikase Therapeutics Major Shareholders This page (NASDAQ:ELYM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELYM Stock Alerts